US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi Genomics & Precision Medicine ETF

37.35

-1.0027-2.61%

Volume:30.55K

Turnover:1.15M

Market Cap:2.80M

PE:- -

High:38.44

Open:38.44

Low:37.35

Close:38.35

52wk High:38.70

52wk Low:23.88

Shares:75.00K

Float Shares:75.00K

Volume Ratio:41.69

T/O Rate:40.73%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

New precision medicine venture gives Syngenis added firepower

The West Australian

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms

Agilent Technologies Inc. Stock Outperforms Competitors on Strong Trading Day

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS

Ultragenyx price target raised to $35 from $32 at Barclays

Correction to Vertex Material Listing Article on Sept. 17

Steris PLC Stock Underperforms Friday When Compared to Competitors

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/GNMX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","market":"US","secType":"STK","nameCN":"Corgi Genomics & Precision Medicine ETF","latestPrice":37.3454,"timestamp":1790884800000,"preClose":38.3481,"halted":0,"volume":30545,"delay":0,"changeRate":-0.026147318902370764,"floatShares":75000,"shares":75000,"eps":0,"marketStatus":"Pre-Mkt","change":-1.0027,"latestTime":"10-02 06:43:38 EDT","open":38.44,"high":38.44,"low":37.3454,"amount":1154709,"amplitude":0.028544,"askPrice":59.37,"askSize":100,"bidPrice":15.02,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1302235200000,"exchange":"CBOE","adjPreClose":37.3454,"nav":38.28,"aum":2871000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.8,"preClose":37.3454,"latestTime":"16:10 EDT","volume":6,"amount":224.0724,"timestamp":1790885403989,"change":0.4546,"changeRate":0.012173,"amplitude":0},"volumeRatio":41.69395644975135,"impliedVol":0.1313,"impliedVolPercentile":0.2979},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","floatShares":75000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":41.69395644975135,"shares":75000,"dividePrice":0,"high":38.44,"amplitude":0.028544,"preClose":38.3481,"low":37.3454,"week52Low":23.88,"pbRate":"--","week52High":38.7,"institutionHeld":0,"latestPrice":37.3454,"eps":0,"divideRate":0,"volume":30545,"delay":0,"ttmEps":0,"open":38.44,"prevYearClose":25.56,"prevWeekClose":38.003,"prevMonthClose":38.3481,"prevQuarterClose":38.3481,"fiveDayClose":38,"twentyDayClose":35.64,"sixtyDayClose":31.6675},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNMX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNMX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GNMX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ9MQY76.HKD","BK4588","IE00B19Z9Z06.USD","IBB","LU0289739699.SGD","MAZE","LU0079474960.USD","LU2089984988.USD","LU1093756168.USD","VRTX","LU0058720904.USD","SGXZ57979304.SGD","IBBQ","LU0234570918.USD","IE00B19Z3581.USD","TBXU","LU2237438978.USD","LU1674673428.USD","LU2324357040.USD","BIB","BK4023","BK4585","LU1035775433.USD","LU0432979614.USD","LU1815336091.USD","IDNA","IE00B894F039.SGD","PBE","IE00BJT1NW94.SGD","LU1430594728.SGD","XBI","LU1069344957.HKD","LU2462157665.USD","IE00B2B36J28.USD","LU2362541513.USD","VERX","LU2236285917.USD","BK4567","LU0889565916.HKD","LU2456880835.USD","BBH","IE00BFTCPJ56.SGD","LU1559883803.SGD","LU1585245621.USD","BK4532","LU0256863811.USD","GNMX","IE0002141913.USD","IE0009355771.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["PBE","TMAT","IOZ.AU","LFSC","MEDX","OZR.AU","OZF.AU","IBB","BK4588","FDIF","HTEC","GDOC","SYNB","WDNA","IIGF.AU","JDOC","IISV.AU","ZYAU.AU","GNMX","SLF.AU","GEAR.AU","BEAR.AU","GIVE.AU","BK4585","IDNA","STW.AU","VAP.AU","XKO.AU","XT","EES","QFN.AU","E200.AU","DACE.AU","ADHD","GNOM","BBOZ.AU","IMLC.AU","EIGA.AU","HELX","XJO.AU","QRE.AU","XAO.AU","VAS.AU","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1674673691.USD","LU2362540622.SGD","LU0823416689.USD","IE0002141913.USD","PBE","SGXZ57979304.SGD","LU1069344957.HKD","LU0256863811.USD","GNMX","LU2362541513.USD","LU0289739699.SGD","VERX","LU2456880835.USD","IE00B19Z9P08.USD","TBXU","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","IE0002270589.USD","VRTX","LU0058720904.USD","LU0079474960.USD","LU1778281490.HKD","LU1093756325.SGD","IE00B894F039.SGD","IE0009355771.USD","IE00B19Z9Z06.USD","IDNA","LU0061475181.USD","BK4023","LU0757428866.USD","LU0320765992.SGD","BK4533","IE00B19Z3581.USD","LU2462157665.USD","LU1585245621.USD","LU1093756168.USD","BK4532","BBH","LU2089984988.USD","LU1559883803.SGD","IBBQ","LU1674673428.USD","LU1035775433.USD","IBB","BK4585","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","PBE","LU2462157665.USD","IE0009355771.USD","LU0234570918.USD","LU0889565916.HKD","IDNA","LU2417539215.USD","BK4139","IE00BFTCPJ56.SGD","LU0058720904.USD","VRTX","IE0002270589.USD","BBH","LU0289739699.SGD","GNMX","LU1559883803.SGD","BK4567","LU0079474960.USD","LU1815336091.USD","LU0432979614.USD","LU0256863811.USD","LU1585245621.USD","SGXZ57979304.SGD","LU1093756325.SGD","LU2456880835.USD","IE00BZ9MQY76.HKD","LU1778281490.HKD","IE00B19Z3581.USD","LU2236285917.USD","TBXU","IE00B894F039.SGD","IE00B19Z9P08.USD","LU2362541273.HKD","IE0002141913.USD","SG9999013999.USD","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4585","LU1093756168.USD","LU1674673428.USD","LU2362541513.USD","LU2089984988.USD","BK4533","BK4023","VERX","BIB","LU0320765992.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0432979614.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","LU0256863811.USD","LU2362540622.SGD","LU1093756168.USD","VRTX","LU0417517546.SGD","LU0889565916.HKD","IE00B894F039.SGD","LU2362541273.HKD","LU1035775433.USD","BBH","BK4139","LU0320765992.SGD","PBE","IE00B19Z3B42.SGD","BK4532","SG9999013999.USD","BK4567","LU0234570918.USD","IE0009355771.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","LU2089984988.USD","BIB","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0061475181.USD","LU1674673691.USD","IE0002141913.USD","LU0079474960.USD","BK4533","IBB","LU2362541513.USD","TBXU","IBBQ","LU0823416689.USD","IDNA","BK4588","GNMX","BK4585","LU2236285917.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU2417539215.USD","LU1093756325.SGD","LU2237438978.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","IE0002270589.USD","SG9999013999.USD","BK4532","IE00BJJMRZ35.SGD","LU2362541513.USD","LU2417539215.USD","IE00B19Z3581.USD","IE0002141913.USD","BK4139","BK4533","LU0566484027.USD","TBXU","LU2362540622.SGD","IE00BZ9MQY76.HKD","LU2089984988.USD","LU1674673428.USD","SG9999001176.SGD","LU0079474960.USD","IE00B19Z9Z06.USD","LU1559883803.SGD","LU1069344957.HKD","BIB","GNMX","IBB","LU1674673691.USD","LU1093756325.SGD","LU2236285917.USD","IE00B894F039.SGD","LU1778281490.HKD","SG9999001176.USD","IE00BJT1NW94.SGD","BBH","PBE","BK4567","LU0061475181.USD","LU0757428866.USD","IE00B19Z9P08.USD","IDNA","VERX","LU1815336091.USD","IE0009355771.USD","BK4588","LU2468319806.SGD","SGXZ57979304.SGD","LU2324357040.USD","LU0058720904.USD","LU1035775433.USD","VRTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LU0234570918.USD","BK4532","LU1093756325.SGD","LU0109394709.USD","LU1778281490.HKD","LU0256863811.USD","GNMX","LU1585245621.USD","LU2362540622.SGD","IE00B19Z9P08.USD","IE00B2B36J28.USD","PBE","LU2236285917.USD","LU1674673428.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","BK4023","VERX","IE00B19Z3581.USD","BK4139","BK4588","IE0002141913.USD","BBH","IBB","BIB","IBBQ","LU1815336091.USD","LU0757428866.USD","LU1035775433.USD","LU0289739699.SGD","IDNA","SG9999001176.SGD","LU0823416689.USD","BK4567","VRTX","TBXU","IE00BJT1NW94.SGD","LU0432979614.USD","LU1093756168.USD","LU1674673691.USD","LU0061475181.USD","IE00B19Z9Z06.USD","IE0009355771.USD","LU1430594728.SGD","LU2462157665.USD","SG9999013999.USD","IE00B19Z3B42.SGD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE0002141913.USD","LU0823416689.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IDNA","LU0889565916.HKD","TBXU","LU0061475181.USD","LU1674673691.USD","BK4588","LU2362541513.USD","LU1035775433.USD","LU2462157665.USD","LU0079474960.USD","LU0256863811.USD","VRTX","LU1093756168.USD","LU1674673428.USD","BK4532","PBE","IE00B19Z3B42.SGD","BK4567","LU2324357040.USD","SG9999013999.USD","IE00B19Z9P08.USD","BK4139","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","SG9999001176.SGD","IE00BZ9MQY76.HKD","IE0002270589.USD","IBB","LU2089984988.USD","BIB","LU0058720904.USD","LU1069344957.HKD","GNMX","LU0320765992.SGD","IBBQ","LU2468319806.SGD","LU2362541273.HKD","LU2237438978.USD","IE0009355771.USD","BK4585","LU0109394709.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756325.SGD","IE00B19Z9P08.USD","LU2324357040.USD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU1674673428.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU2236285917.USD","LU2237438978.USD","BIB","LU2362541513.USD","LU1069344957.HKD","IE00B19Z9Z06.USD","BK4585","LU0079474960.USD","LU1093756168.USD","LU1585245621.USD","LU2362541273.HKD","LU0889565916.HKD","BBH","LU0234570918.USD","GNMX","LU0109394709.USD","LU2417539215.USD","LU0417517546.SGD","SGXZ57979304.SGD","SG9999001176.SGD","IE0002141913.USD","IBBQ","VRTX","LU2468319806.SGD","IBB","TBXU","LU2362540622.SGD","IDNA","BK4139","IE00B894F039.SGD","LU2456880835.USD","LU0289739699.SGD","LU0823416689.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2462157665.USD","IE0002270589.USD","PBE","LU0256863811.USD","IE00BJJMRZ35.SGD","LU1674673691.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541513.USD","LU0234570918.USD","BK4585","IDNA","IE00B19Z9P08.USD","LU0256863811.USD","IBB","BIB","IE00BZ9MQY76.HKD","PBE","LU0079474960.USD","LU2324357040.USD","LU1674673428.USD","LU1069344957.HKD","LU2462157665.USD","LU0320765992.SGD","VRTX","LU0061475181.USD","IE00B4R5TH58.HKD","GNMX","LU0889565916.HKD","LU0432979614.USD","LU1035775433.USD","LU2089984988.USD","LU2456880835.USD","IE0002141913.USD","LU2417539215.USD","IE00BJT1NW94.SGD","IE0002270589.USD","LU0058720904.USD","SGXZ57979304.SGD","BK4588","LU1585245621.USD","TBXU","BBH","LU0109394709.USD","LU2362541273.HKD","BK4533","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","BK4532","LU2237438978.USD","BK4139","SG9999013999.USD","BK4567","LU1093756325.SGD","SG9999001176.USD","SG9999001176.SGD","LU1778281490.HKD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU1035775433.USD","LU0109394709.USD","LU1069344957.HKD","LU1093756325.SGD","BK4532","SG9999013999.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z3581.USD","BK4585","LU1778281490.HKD","LU1674673691.USD","LU0079474960.USD","IBB","IE0002141913.USD","IE00B2B36J28.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2456880835.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU0432979614.USD","GNMX","TBXU","BK4139","LU0234570918.USD","LU2089984988.USD","BBH","LU0061475181.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193923","title":"Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193923?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:59","pubTimestamp":1790024393,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics ( ($IMDX) ) has issued an announcement. Insight Molecular Diagnostics Inc. operates in the molecular diagnostics indu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/insight-molecular-diagnostics-revises-chronix-royalty-agreement-terms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/insight-molecular-diagnostics-revises-chronix-royalty-agreement-terms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HTEC","BMED","GNMX","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193678","title":"Agilent Technologies Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193678","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193678?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:51","pubTimestamp":1790023860,"startTime":"0","endTime":"0","summary":"DJ Agilent Technologies Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Agilent Technologies Inc.  rose 3.50% to $161.94 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 1.49% to 7,764.70 and the Dow Jones Industrial Average  rising 0.71% to 52,048.83.This was the stock's fifth consecutive day of gains.Agilent Technologies Inc. closed 1.11% short of its 52-week high of $163.75, which the company achieved on August 27th.The stock outperformed some of its competitors Monday, as Thermo Fisher Scientific Inc.  rose 1.12% to $658.76, Danaher Corp.  rose 1.90% to $215.84, and Abbott Laboratories  rose 0.36% to $102.98.Trading volume  eclipsed its 50-day average volume of 2.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0061474960.USD","BK4588","SGXZ41872573.SGD","LU0316494557.USD","LU0170899867.USD","BK4534","LU1057294990.SGD","LU2125910336.SGD","DHR","LU0528227936.USD","SGXZ57979304.SGD","BK4581","LU1791710582.SGD","LU0058720904.USD","LU2125909916.SGD","LU0211331839.USD","LU2433249047.HKD","LU1804176565.USD","A","IHI","TMO","HRTS","IE0002141913.USD","LU2360108059.USD","TMED","LU0689472784.USD","LU2089279066.USD","ABT","LU0011850046.USD","LU2133065610.SGD","IE000M9KFDE8.USD","FMED","LU2063271972.USD","LU1712237335.SGD","LU1670627923.USD","PJP","LU2298321311.HKD","LU1551013425.SGD","LU2125909759.SGD","LU0289960550.SGD","LU0345770308.USD","LU2543165471.USD","IE00BJT1NW94.SGD","LU0266013472.USD","GNMX","LU1917777945.USD","LU1551013342.USD","BK4082","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MRNY","NSPR","BK4585","PSCH","BK4588","BBP","IEIH","RSPH","TBXU","BK4198","MEDI","GDOC","NVIB","IBB","PINK","LFSC","MRNX","BMED","GNMX","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150936","title":"Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150936?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:40","pubTimestamp":1789987218,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Innate Pharma (IPHA) and Alnylam Pharma (ALNY) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-innate-pharma-ipha-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-innate-pharma-ipha-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4139","PBE","IPHA","GNMX","BK4585","HCSG","LABU","LU0128526141.USD","ALNY","LU0882574055.USD","BK4137","XBI","BK4548","BK4588","XLV","LU0320765992.SGD","LU0029874061.USD","LU0109394709.USD","BK4581","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315293","title":"Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315293?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","PBE","LU1069344957.HKD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","IDNA","VRTX","BIB","LU0320765992.SGD","IE00B894F039.SGD","GNMX","IE00BZ9MQY76.HKD","LU2362541273.HKD","LU2468319806.SGD","IE00B19Z9P08.USD","IE00B19Z3581.USD","BBH","LU2362540622.SGD","LU0109394709.USD","LU1585245621.USD","LU2362541513.USD","LU2089984988.USD","LU0256863811.USD","LU0289739699.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","LU2324357040.USD","IE0009355771.USD","SG9999001176.SGD","IE00BFTCPJ56.SGD","BK4567","LU1093756168.USD","LU0061475181.USD","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","LU2236285917.USD","IBB","BK4533","BK4139","TBXU","LU2417539215.USD","BK4588","LU0058720904.USD","LU1778281490.HKD","LU1035775433.USD","IE00BJT1NW94.SGD","IBBQ","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","BK4588","LABU","PSCH","RSPH","GDOC","BK4139","MRNX","RARE","PINK","SYNB","IBB","MEDI","GNMX","LFSC","TECB","XLVX","MRNY","BK4585","IYH","IEIH","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412132","title":"Correction to Vertex Material Listing Article on Sept. 17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412132?lang=en_us&edition=fundamental","pubTime":"2026-09-21 12:48","pubTimestamp":1789966080,"startTime":"0","endTime":"0","summary":"Tan Chin Teong is the founder and technical director of Vertex Material. \"Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing,\" at 0931 GMT on Sept. 17, misstated the name as Tan Chin Tong.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0823416689.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IDNA","LU0889565916.HKD","TBXU","BK4588","LU2362541513.USD","LU1035775433.USD","LU2462157665.USD","LU0079474960.USD","LU0256863811.USD","LU1778281490.HKD","VRTX","LU1093756168.USD","PBE","IE00B19Z3B42.SGD","BK4567","LU2324357040.USD","SG9999001176.USD","SG9999013999.USD","IE00B19Z9P08.USD","LU0417517546.SGD","LU0566484027.USD","IE00BFTCPJ56.SGD","LU2236285917.USD","SG9999001176.SGD","LU2362540622.SGD","LU0234570918.USD","LU1585245621.USD","IBB","LU2089984988.USD","BIB","LU0058720904.USD","LU1069344957.HKD","GNMX","LU0320765992.SGD","IBBQ","BK4023","VERX","LU2468319806.SGD","LU2362541273.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE00B894F039.SGD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668753169","title":"Steris PLC Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668753169","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668753169?lang=en_us&edition=fundamental","pubTime":"2026-09-19 05:05","pubTimestamp":1789765500,"startTime":"0","endTime":"0","summary":"DJ Steris PLC Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Steris PLC  slid 1.44% to $205.04 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.17% to 7,650.50 and the Dow Jones Industrial Average  falling 0.18% to 51,682.64.This was the stock's fourth consecutive day of losses.Steris PLC closed 23.90% below its 52-week high of $269.44, which the company achieved on January 16th.The stock underperformed when compared to some of its competitors Friday, as Thermo Fisher Scientific Inc.  fell 1.04% to $651.45, Danaher Corp.  fell 0.32% to $211.81, and Becton Dickinson & Co.  fell 0.24% to $180.94.Trading volume  eclipsed its 50-day average volume of 691,868.Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","IHI","LU1974910355.USD","DHR","FMED","LU0648000940.SGD","LU0011850046.USD","LU1791710400.SGD","BDX","LU1854103824.USD","LU2125910336.SGD","LU2543165471.USD","HRTS","GNMX","TMED","LU0251142724.SGD","LU1059921491.USD","LU2125909916.SGD","LU0266013472.USD","LU2106854487.HKD","LU2125909759.SGD","LU0433182093.SGD","LU2089984988.USD","LU1633808545.USD","IE00B4R5TH58.HKD","LU0345770308.USD","IE0009355771.USD","SG9999001176.SGD","IE00BFTCPJ56.SGD","LU0072461881.USD","LU0128525929.USD","LU1548497426.USD","LU0289961442.SGD","LU0130518102.USD","LU0640476718.USD","LU0477156797.USD","LU2092937221.SGD","LU0162691827.USD","SGXZ23171101.USD","IE00BQXX3D17.EUR","LU2433249047.HKD","IE00B19Z8X17.USD","SG9999001176.USD","LU0557290698.USD","LU1803068623.USD","LU0943347566.SGD","LU2360108059.USD","TMO","STE","LU0820561818.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4588","BK4007","LFSC","GNMX","IBB","TECB","PINK","PSCH","XLVX","SYNB","TBXU","BK4585","GDOC","MRNX","FRTY","BMED","NVIB","MRNY","IDNA","IYH","IEIH","MEDI","AMRX","LABU","BBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}